TUNIGHT + TUMORROW

For the maintenance treatment of COPD, TUDORZA significantly reduced exacerbations and improved lung function with an evening and morning dose1-5

Tudorza® Pressair® is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy).1

Improved Lung Function*

Improved bronchodilation (FEV1) with a dose in the evening and the morning1-4,6

Reassuring Dual Feedback

Provides visual cues (color-controlled window) and an audible click when patients inhale their dose correctly

Savings Guarantee Program

Eligible commercially insured patients receive their prescription for $10, even those who are commercially rejected

Request Samples Today

Use our simple and easy online ordering system to get samples delivered directly to your office.

Request Samples

*Please refer to study designs and additional relevant data.
Feedback mechanisms consist of visual cues (color-controlled window and an audible “click”).
Subject to eligibility; restrictions apply.

Important Safety Information

  • TUDORZA PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients
  • TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy)
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of TUDORZA PRESSAIR. Additionally, inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm. If any of these occurs, treatment with TUDORZA PRESSAIR should be stopped and other treatments considered
  • TUDORZA PRESSAIR should be used with caution in patients with narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any worsening of glaucoma or worsening of urinary retention develop
  • The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA PRESSAIR vs placebo, respectively. In a long-term cardiovascular safety trial of up to 3 years, the adverse reactions (occurring at a rate of ≥2% and more common than placebo) were nausea, back pain, cough, hypertension, sinusitis, constipation, arthralgia, anemia, muscle spasms, cardiac failure congestive, cellulitis, and gastroesophageal reflux disease

INDICATIONS AND USAGE

Tudorza® Pressair® (aclidinium bromide inhalation powder) is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

TUDORZA is not a rescue medicine and should not be used for treating sudden breathing problems. Your doctor may give you other medicine to use for sudden breathing problems.

Please also see the full Prescribing Information, including Patient Information.

ADVERSE REACTIONS

You are encouraged to report any TUDORZA adverse events by calling 1-833-614-9269. If you prefer to report these to the FDA, either visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Who should not use TUDORZA PRESSAIR?
TUDORZA PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients

Important Safety Information

  • TUDORZA PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients
  • TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy)
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of TUDORZA PRESSAIR. Additionally, inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm. If any of these occurs, treatment with TUDORZA PRESSAIR should be stopped and other treatments considered
  • TUDORZA PRESSAIR should be used with caution in patients with narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any worsening of glaucoma or worsening of urinary retention develop
  • The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA PRESSAIR vs placebo, respectively. In a long-term cardiovascular safety trial of up to 3 years, the adverse reactions (occurring at a rate of ≥2% and more common than placebo) were nausea, back pain, cough, hypertension, sinusitis, constipation, arthralgia, anemia, muscle spasms, cardiac failure congestive, cellulitis, and gastroesophageal reflux disease

INDICATIONS AND USAGE

Tudorza® Pressair® (aclidinium bromide inhalation powder) is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

TUDORZA is not a rescue medicine and should not be used for treating sudden breathing problems. Your doctor may give you other medicine to use for sudden breathing problems.

Please also see the full Prescribing Information, including Patient Information.

ADVERSE REACTIONS

You are encouraged to report any TUDORZA adverse events by calling 1-833-614-9269. If you prefer to report these to the FDA, either visit www.fda.gov/medwatch or call 1-800-FDA-1088.

REFERENCES: 1. Tudorza® Pressair® (aclidinium bromide inhalation powder) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019. 2. Kerwin EM, D’Urzo AD, Gelb AF, et al; on behalf of the ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).COPD.2012;9:90-101. 3. Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig.2013;33:893-904. 4. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.Eur Respir J. 2012;40:830-836. 5. Wise RA, Chapman KR, Scirica BM, et al. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. JAMA. 2019;321(17):1693-1701. doi:10.1001/jama.2019.4973. 6. Singh D, Magnussen H, Kirsten A, et al. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther. 2012;25:248-253.